Mavacamten in hypertrophic obstructive cardiomyopathy: Prospects for AI integration and mitigating healthcare disparities
Authors:
- Samia Aziz SulaimanSSSamia Aziz Sulaiman
- Ahmad E. SaeedASAhmad E. Saeed
- Abdulrahman Nasir Al KhatibAKAbdulrahman Nasir Al Khatib
- Saif YaminSaif Yamin
- Hamzeh Faisal MohammedHMHamzeh Faisal Mohammed
- Own Ma'En Abu RummanOROwn Ma'En Abu Rumman
- Haya Amjad AbidaHAHaya Amjad Abida
- Hritvik JainHJHritvik Jain
- Aman GoyalAGAman Goyal
- 8 August 2024
- journal article
- review article
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (11) , 102786
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic CardiomyopathyJACC: Advances, 2023
- Mavacamten: First ApprovalDrugs, 2022
- Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to BedsideDrugs, 2022
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2021
- Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive CardiomyopathyCurrent Cardiology Reports, 2021
- Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescentsInternational Journal of Cardiology, 2021
- Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)American Heart Journal, 2021
- Lessons From MAVERICK-HCMJACC, 2020
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyJACC, 2020
- Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled ElectrocardiogramJACC, 2020